Filing identity and reporting period
Important mismatch: The supplied filing is Isoray, Inc.’s Form 10-Q for the quarter ended September 30, 2020, filed November 13, 2020. It is not a filing for Perspective Therapeutics. The company describes itself as a manufacturer of Cesium-131 brachytherapy products.
Financial performance
Amounts below are in millions of dollars unless stated otherwise. The quarter ended September 30, 2020 is compared with the quarter ended September 30, 2019.
| Metric | 2020 | 2019 | Change |
|---|---|---|---|
| Net sales | $2.384 | $2.315 | +3% |
| Gross profit | $1.246 | $1.236 | +1% |
| Gross margin | 52% | 53% | Down about 1 percentage point |
| Operating expenses | $1.960 | $2.072 | -5% |
| Operating loss | $(0.714) | $(0.836) | Loss narrowed 15% |
| Net loss | $(0.713) | $(0.816) | Loss narrowed |
| Operating cash used | $(0.338) | $(0.653) | Use decreased |
| Investing cash used | $(0.113) | $(0.098) | Use increased |
Sales mix shifted: prostate brachytherapy sales fell 9% to $1.890 million, while other sales rose 104% to $0.494 million, with brain-cancer treatments including GammaTile identified as a key contributor. Cost of sales increased 5%, reflecting isotope freight and labor costs and some unused isotope inventory. Research and development expense rose 34% to $0.312 million; sales and marketing expense declined 29% to $0.581 million, partly due to COVID-related reductions in travel and events.
Liquidity, capital and obligations
At September 30, 2020, cash and cash equivalents were $1.940 million, restricted cash was $0.182 million, working capital was $3.224 million, and the current ratio was 3.12. Cash, cash equivalents and restricted cash together totaled $2.122 million, down $0.451 million during the quarter. Total assets were $8.025 million and total liabilities were $2.930 million. The filing reports lease liabilities of $0.956 million, including $0.241 million current and $0.715 million non-current; it does not report conventional borrowings in the presented balance sheet.
After quarter-end, on October 22, the company sold 18.27 million shares for gross proceeds of $9.5 million and estimated net proceeds of approximately $8.66 million. It also issued warrants for up to 9.13 million shares at $0.57 per share, exercisable immediately and expiring after five years. Management said it did not anticipate needing additional capital raises to finance operations during the next fiscal year.
Outlook, commentary and key risks
- Management’s fiscal 2021 planning assumption called for approximately 25% annual revenue growth; the company missed that growth target in the first quarter. Reaching cash-flow break-even in three to four years is conditional on achieving and sustaining the growth strategy, with no assurance it will do so.
- Management attributed weaker prostate procedure demand to COVID-19 disruptions, including delayed or cancelled procedures. It reported sales remained below the average monthly level reached before the pandemic’s effects and warned that renewed COVID-19 impacts could further affect demand and operations.
- Cesium-131 supply depends on Russian sources and international freight. Reactor shutdowns and flight disruptions could constrain supply. A new supply contract runs from August 2020 through December 2021.
- Three customers accounted for approximately 42% of revenue; one physician-group customer group accounted for about 26%. The filing also says this group represented 25.68%, indicating a small difference in disclosed percentages. Customer loss or changes in prostate-treatment demand could materially affect sales.
- Reimbursement remains uncertain. New inpatient billing codes took effect October 1, 2020, and CMS delayed the Radiation Oncology Alternative Payment Model’s effective date to July 1, 2021. Management had not determined the rule’s likely effect on the business.
- The company has no off-balance-sheet arrangements and reported no material changes to its previously disclosed risk factors other than the customer concentration and COVID-related disclosures described in the filing.
Most important facts to verify
- Confirm the issuer and period: this source is Isoray’s quarter ended September 30, 2020, not Perspective Therapeutics’ 2020 Q1.
- Reconcile the revenue-mix disclosure: the filing’s table shows prostate sales of $1.890 million, or 79% of sales, while another note states prostate brachytherapy was 81%.
- Assess cash runway and the effect of the post-quarter equity financing and warrants, including potential dilution and whether proceeds support the stated next-fiscal-year funding outlook.
- Monitor COVID-related procedure volumes, Russian isotope supply and freight continuity, customer concentration, and reimbursement developments.